Article
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.
Cancer immunology, immunotherapy : CII - 11 May 2026
Radovich Milan, Wacker James, Solzak Jeffrey, Tae Hongseok, Ribeiro Jennifer R, Maney Todd, Hancock Bradley, Hamrick James, Sledge George W, Ahluwalia Manmeet S, Liu Stephen V, Lou Emil, Subbiah Vivek, Halmos Balazs, Magee Daniel, Spetzler David B
Abstract excerpt
Although the tissue-agnostic FDA approval of pembrolizumab for tumor mutational burden (TMB)-high tumors has provided meaningful clinical benefit to patients, there remains a need to optimize TMB assessment. In this cohort study, we investigated the discordance between whole-exome sequencing (WES) and panel-based methods and evaluated their relative clinical utility in identifying patients likely to benefit from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.